Nelson R&D drug patent
Firm said it received a U.S. patent, No. 4,564,628, for "a potent new drug candidate for the treatment of Parkinson's disease, glaucoma, and hyperprolactinemia." Nelson said clinical trials of the compound, known as N-0437, for the treatment of Parkinson's disease and glaucoma are scheduled to begin this year.
You may also be interested in...
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.